MARKET

ALZN

ALZN

Alzamend Neuro Inc
NASDAQ
1.100
+0.100
+10.00%
Opening 15:50 03/27 EDT
OPEN
1.000
PREV CLOSE
1.000
HIGH
1.100
LOW
0.9703
VOLUME
148.91K
TURNOVER
--
52 WEEK HIGH
15.06
52 WEEK LOW
0.6427
MARKET CAP
7.26M
P/E (TTM)
-0.3572
1D
5D
1M
3M
1Y
5Y
1D
Alzamend Neuro announces initiation date of Phase II trial of AL001
TipRanks · 2d ago
Alzamend Neuro Announces Phase II Trial Of AL001 For Alzheimer's In Q4 2025 In Partnership With Massachusetts General Hospital
Benzinga · 2d ago
ALZAMEND NEURO ANNOUNCES INITIATION DATE OF PHASE II CLINICAL TRIAL OF AL001 FOR TREATMENT OF ALZHEIMER’S DISEASE TO TAKE PLACE AT MASSACHUSETTS GENERAL HOSPITAL
Reuters · 2d ago
Weekly Report: what happened at ALZN last week (0317-0321)?
Weekly Report · 4d ago
ALZAMEND NEURO INC: PLANS TO INITIATE PHASE II CLINICAL STUDY OF AL001 FOR TREATMENT OF PATIENTS WITH MDD IN Q4 OF 2025
Reuters · 03/18 12:09
Alzamend Neuro Plans Initiation Date Of Phase II Clinical Trial Of AL001 For Major Depressive Disorder
Benzinga · 03/18 12:07
Alzamend Neuro Price Target Cut to $20.00/Share From $32.00 by Ascendiant Capital
Dow Jones · 03/17 11:58
Ascendiant Capital Maintains Buy on Alzamend Neuro, Lowers Price Target to $20
Benzinga · 03/17 11:48
More
About ALZN
Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel products for the treatment of Alzheimer's disease (Alzheimer's), bipolar disorder (BD), major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). The Company's pipeline consists of two novel therapeutic drug candidates: AL001, and ALZN002. AL001 is a patented ionic cocrystal technology delivering a therapeutic combination of lithium, salicylate and L-proline through three royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc., (the Licensor). AL001 is used for Alzheimer's, BD, MDD and PTSD treatment. ALZN002 is a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer's by removing beta-amyloid from the brain through a royalty-bearing exclusive worldwide license from the Licensor.

Webull offers Alzamend Neuro Inc stock information, including NASDAQ: ALZN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALZN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALZN stock methods without spending real money on the virtual paper trading platform.